Examkin

Soru

Zorluk: OrtaHematology and Oncology

A hospital rapid response team is called to the bedside of a 58-year-old female inpatient due to acute right leg pain and swelling. The patient was admitted six days ago for an acute non-ST-segment elevation myocardial infarction and has been receiving a continuous intravenous infusion of unfractionated heparin since admission. Her other medications include aspirin, atorvastatin, and metoprolol. Temperature is 37.1°C (98.8°F), blood pressure is 135/85 mmHg, pulse is 92/min, and respirations are 16/min. Physical examination of the right lower extremity reveals significant edema from the calf to the mid-thigh with localized tenderness, but peripheral pulses remain palpable. Laboratory results on admission showed a platelet count of 260,000/mm³. Today's laboratory studies reveal a hemoglobin of 13.1 g/dL, leukocyte count of 8,200/mm³, and a platelet count of 65,000/mm³. A stat lower extremity compression ultrasonography confirms a new, occlusive deep venous thrombosis in the right femoral vein. Which of the following is the most appropriate next step in the management of this patient?

  1. Discontinue unfractionated heparin and initiate an argatroban infusionCevap
  2. B
    Discontinue unfractionated heparin and initiate oral warfarin therapy
  3. C
    Discontinue unfractionated heparin and administer subcutaneous enoxaparin
  4. D
    Continue unfractionated heparin and administer a prophylactic platelet transfusion
  5. E
    Order a serotonin release assay and maintain the current heparin infusion pending results

Cevap

The most appropriate next step is to discontinue all heparin products and initiate a direct thrombin inhibitor, such as argatroban.
The patient's clinical picture is highly characteristic of Heparin-Induced Thrombocytopenia (HIT) Type 2. She has a precipitous (>50%) drop in platelets occurring 5 to 10 days after heparin exposure, complicated by a new thrombotic event (femoral DVT). HIT is caused by IgG autoantibodies targeting complexes of heparin and Platelet Factor 4 (PF4), which leads to widespread platelet activation and consumption. When clinical suspicion is high (indicated by a high 4T score), all forms of heparin must be stopped immediately. To manage the ongoing hypercoagulable state and the new DVT, a non-heparin alternative anticoagulant must be initiated promptly. Direct thrombin inhibitors like argatroban or bivalirudin, or the factor Xa inhibitor fondaparinux, are the agents of choice.

Adım Adım Çözüm

1
Analyze the patient's presentation and timeline.
The patient developed a >50% drop in platelet count (from 260,000 to 65,000) occurring exactly 6 days after the initiation of unfractionated heparin.
Establishing the timeline and magnitude of thrombocytopenia is required to calculate the 4T score for suspected Heparin-Induced Thrombocytopenia (HIT).
2
Assess for complications of the thrombocytopenia.
The patient has concurrently developed a new deep venous thrombosis (DVT) in the right femoral vein.
HIT is paradoxically a highly prothrombotic state; the presence of a new thrombosis makes the clinical diagnosis of HIT Type 2 extremely likely.
3
Determine the necessary immediate therapeutic intervention.
All forms of heparin must be immediately discontinued, and an alternative, non-heparin anticoagulant must be started to treat the active DVT.
Continuing heparin or delaying treatment fuels the immune-mediated thrombosis. Argatroban (a direct thrombin inhibitor) is a preferred alternative anticoagulant in this scenario.

Anahtar Kavram

Patients with a high clinical suspicion for Heparin-Induced Thrombocytopenia (HIT) Type 2 must have all heparin products immediately discontinued and an alternative non-heparin anticoagulant (e.g., argatroban, fondaparinux) started empirically.
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru